People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OrthoBio Therapeutics, Inc. | — | Biotechnology | Series B | $31.4M | $147.5M | 2025 |
Jessica T. Hopfield at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jessica T. Hopfield on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stanley T. Shuman | 1 | 1 |
| Marc J. Prisant | 1 | 1 |
| Peter J. Millett | 1 | 1 |
| Lodewijk J. De Vink | 1 | 1 |
| William T. Esrey | 1 | 1 |
| Robert T. Hugin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.